Researchers at the University of Saskatchewan are accelerating efforts to develop hantavirus treatments following a deadly outbreak aboard a cruise ship.

This research push is critical because the virus can cause severe respiratory failure and has a high mortality rate. The current lack of specific antiviral treatments means clinicians must rely on supportive care, making the identification of new therapeutic targets a public health priority.

Scientists at the university's infectious-disease laboratory, including researchers from the Veterinary Infectious Disease Organization, are comparing immune responses in humans and deer mice [1]. By analyzing these different biological reactions, the team aims to identify specific proteins or pathways that can be targeted with medication to stop the virus from replicating [1].

The urgency for these findings follows an outbreak of the Andes-strain hantavirus on the MV Hondius cruise ship [2]. That specific event resulted in three deaths [2]. The Andes strain is particularly concerning to health officials because, unlike many other hantaviruses, it can be transmitted from person to person [2].

Researchers in Saskatoon are utilizing advanced virology tools to map how the virus interacts with host cells [1]. The goal is to create a treatment that can be deployed rapidly during future outbreaks to reduce the fatality rate associated with the disease [1].

While the laboratory work is intensifying, the team continues to study the genetic makeup of the virus to ensure treatments remain effective against mutating strains [1]. The collaboration between human and veterinary scientists allows for a broader understanding of the zoonotic jump, the process by which a virus moves from animals to humans [1].

“The current lack of specific antiviral treatments means clinicians must rely on supportive care.”

The shift toward comparative immunology between humans and deer mice suggests a strategy to find 'universal' vulnerabilities in the hantavirus family. Because the Andes strain allows for human-to-human transmission, the risk of localized outbreaks evolving into larger public health crises is higher than with other strains, necessitating a move from supportive care to active pharmaceutical intervention.